Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers

Inclusion Criteria

• •Patients with metastatic colorectal cancer whose tumor has progressed on both FOLFOX and FOLFIRI.
• •Exception: Patients with metastatic colorectal cancer whose tumors demonstrate a BRAF V600E mutation may be enrolled regardless of prior chemotherapy.
• •Exception: Patients whose tumors are MSI-H must have experience progression through immunotherapy in addition to the therapies mentioned above.
• •Patients with metastatic pancreatic adenocarcinoma.
• •Patients with metastatic gastric or esophageal cancer whose tumor has progressed through first-line chemotherapy of any type.
• •Patients with metastatic cholangiocarcinoma whose tumor has progressed through first-line chemotherapy of any type.
• •Patients with metastatic hepatocellular carcinoma whose tumor has progressed through PD1 blockade.
• •Patients with metastatic high-grade neuroendocrine tumor.
• •A patient with a metastatic GIST that has progressed through first-line tyrosine kinase inhibitor.
• •Expected life expectancy of at least one month